Month: May 2018

NEDO starts „space business investment matching platform“

The government is working on revitalizing the space industry in Japan. The „S-Matching) is intended to facilitate matching between individuals and venture companies having new business ideas in the space field. Together with public and private sectors such as Japan Bank for Policy Development and Investment (DBJ) and the Industrial Innovation Organization (INCJ), it will […]

Chugai releases tocilizumab (Actemra) for treatment of cytokine-release syndrome (CRS)

Chugai Pharmaceutical announced that the humanized anti-human IL-6 receptor monoclonal antibody Actemra® for intravenous infusion 80 mg, 200 mg, 400 mg” : Tocilizumab (genetic recombination)] (hereinafter referred to as Actemra) was approved by the MHLW for an additional indication for “cytokine release syndrome associated with chimeric antigen receptor gene-introduced T cell infusion therapy”. This application […]

Japan boosts 43 clinical trials on 38 regenerative medicine products

According to a review by Nikkei Biotech, this number relates to doctor-initiated and company clinical trials under control of the Pharmaceutical and Medical Devices Agency. Regenerative medicine is classified into cell medicine” which administers cells in loose state, “regenerative medicine” which transplant cells in a three-dimensional structure and “gene therapy” which administers genetically modified cells […]

GlyTech Inc. reports capital increase, partially from Italy’s MIAT SpA

GlyTech is an Osaka venture founded in 2011. The business focus is on the synthesis of human-type glycosides applicable to the chemical synthesis of highly pure human glycoproteins, Investment is from Nippon Shokubai, Fushimi Seiyaku, SBI Investment, Osaka University Venture Capital, and Italy’s MIAT SpA, a Milano-based chemical trader and investor. GlycoTech news release, […]

Scroll to top